Latest News
Aldeyra Therapeutics Raises USD 74.7m from Common Stock Offering
20 January 2021 - - US-based biotechnology company Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) has closed its underwritten public offering of 7,868,421 shares of its common stock at a public offering price of USD 9.50 per share, including 1,026,315 add...
Stem Cell and Research Therapy Publishes Preclinical Data Highlighting the Potential of a NurOwn Derived Exosome-Based Treatment for COVID-19 ARDS
20 January 2021 - - US-based adult stem cell therapies developer BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) is highlighting the peer-reviewed publication of a preclinical study in the journal Stem Cell and Research Therapy, the c...
Qiagen Plans 1Q21 Resubmit of EUA Submission in the US for QIAreach SARS-CoV-2 Antigen Test
20 January 2021 - - German sample and assay technologies provider Qiagen N.V. (NYSE: QGEN) plans to resubmit in 1Q21 its QIAreach SARS-CoV-2 Antigen Test to the US Food and Drug Administration for Emergency Use Authorization to detect SARS-CoV-2 anti...
US FDA Accepts for Priority Review Application for Opdivo Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
20 January 2021 - - The US Food and Drug Administration has accepted its supplemental Biologics License Application for Opdivo (nivolumab), in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the treatment of pat...
First Patient Dosed in Phase 1 Clinical Trial Evaluating FT-7051 for the Treatment of Metastatic Castration-resistant Prostate Cancer
20 January 2021 - - The first patient has been dosed in a Phase 1 clinical trial evaluating FT-7051, a selective inhibitor of CBP/p300, a known co-activator of the androgen receptor in men with metastatic castration-resistant prostate cancer (mCRPC),...